Clinical Trial Update: Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... [Phase 2]

View source ↗

Summary

Two randomized Phase II studies evaluated AZD6244 with erlotinib versus erlotinib alone in KRAS wild-type and KRAS-mutant advanced non-small cell lung cancer; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD6244 (selumetinib)
• Tarceva (erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Non Small Cell Lung Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2014-10-29